Vaccines for COVID-19: Where do we stand in 2021?

被引:61
|
作者
Sharma, Ketaki [1 ,2 ]
Koirala, Archana [1 ,2 ,3 ]
Nicolopoulos, Katrina [1 ]
Chiu, Clayton [1 ,2 ]
Wood, Nicholas [1 ,2 ]
Britton, Philip N. [2 ,4 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词
COVID-19; SARS-CoV-2; Vaccines; vaccines; NCOV-19; AZD1222; VACCINE; EFFICACY; BNT162B2; SCOTLAND; RISK;
D O I
10.1016/j.prrv.2021.07.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [1] Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar, Tushar
    Raut, Dezaree
    Bhatt, Lokesh Kumar
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2021, 43 (01) : 8 - 21
  • [2] Myocarditis and COVID-19: Where Do We Stand?
    Jakstaite, Aiste Monika
    Papathanasiou, Maria
    Luedike, Peter
    AKTUELLE KARDIOLOGIE, 2021, 10 (01) : 27 - 31
  • [3] COVID-19 in Children: Where do we Stand?
    Nikolopoulou, Georgia B.
    Maltezou, Helena C.
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 1 - 8
  • [4] COVID-19 and AKI: Where Do We Stand?
    Palevsky, Paul M.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (05): : 1029 - 1032
  • [5] COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Lundstrom, Kenneth
    VIRUSES-BASEL, 2024, 16 (02):
  • [6] Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
    Joshi, Gaurav
    Borah, Pobitra
    Thakur, Shweta
    Sharma, Praveen
    Mayank
    Poduri, Ramarao
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 4714 - 4740
  • [7] COVID-19 and liver injury: where do we stand?
    Papadopoulos, Nikolaos
    Vasileiadi, Sofia
    Deutsch, Melanie
    ANNALS OF GASTROENTEROLOGY, 2020, 33 (05): : 459 - 464
  • [8] Coronavirus (COVID-19) and stress: Where do we stand in this journey and where are we leading to!
    Avinash, Bhagyalakshmi
    Sadashivamurthy, Prashanth
    Shivamallu, Avinash Bettahalli
    Ali, Irfan
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2022, 14 : 1087 - 1089
  • [9] Mucosal Vaccines: Where Do We Stand?
    Kraehenbuhl, Jean-Pierre
    Neutra, Marian R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (20) : 2609 - 2628
  • [10] Laboratory biomarkers and prognosis in Covid-19, where do we stand?
    Israni, Alisha
    Goulden, Christopher J.
    Harky, Amer
    REVIEWS IN MEDICAL VIROLOGY, 2021, 31 (06)